New modalities of cancer treatment for NSCLC: focus on immunotherapy
about
Chronic inorganic arsenic exposure in vitro induces a cancer cell phenotype in human peripheral lung epithelial cellsComplex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein.Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.Cellular and molecular immunology of lung cancer: therapeutic implications.FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.Gastric cancer--epidemiologic and clinical aspects.Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use?Epigenetics in lung cancer diagnosis and therapy.Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.Understanding immunotherapy for the treatment of non-small cell lung cancer.Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics.Macrophages, Inflammation, and Lung Cancer.The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy.Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials.How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know.Crizotinib targets in glioblastoma stem cells.The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer.Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC).The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
P2860
Q28394865-BB7DA1A3-FB57-482B-984A-20F5B72CB757Q33417707-F0EEA611-AF04-4597-B305-149D4D3983B6Q35944106-17BE9E0C-7C2E-47FE-8B69-0970ABAF09D7Q36130505-68CF1C3A-8DCF-431E-A764-86F9EDC1CC99Q36884429-8404EF9F-C59A-4EC4-9832-E085B24F9CA6Q38244256-BF8E86BF-743A-41F6-999D-A61910E233B9Q38323055-AFA9BD85-DB2E-479E-826E-C233D76FC84BQ38457939-4AC60C1A-A9AE-45C1-8DF1-9358CA5F3CF0Q38870763-5EC82F1D-5646-4DF0-8399-2BF257458E21Q38951280-3804937E-FBBE-473A-B86E-CA01A97D7ED5Q39110385-A08F278F-61BB-4856-82BE-C7A46AF0123DQ39641416-32409F6E-A477-4A3D-A92A-1348606FE1FEQ41113415-C7A40400-FE5A-465F-B408-963CA2FE6089Q41149149-C2CAF499-5B5C-48DA-9E02-23E5E08DAB5CQ41714695-75314199-8DEC-42CA-89CB-2B77EF54883DQ47120953-FB4A2EEA-8954-4752-A105-C63D7551AC70Q47122191-CD038C84-9745-420E-870C-6AE73601B760Q47144850-F2372FE9-4DA8-49D5-A234-2FBA14CCA68AQ55005404-70CF69EA-C1C9-4703-BE32-3BD7675329B2Q55717841-79991DAC-D194-4C22-83E1-FE7F5B91CD8A
P2860
New modalities of cancer treatment for NSCLC: focus on immunotherapy
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
New modalities of cancer treatment for NSCLC: focus on immunotherapy
@ast
New modalities of cancer treatment for NSCLC: focus on immunotherapy
@en
New modalities of cancer treatment for NSCLC: focus on immunotherapy
@nl
type
label
New modalities of cancer treatment for NSCLC: focus on immunotherapy
@ast
New modalities of cancer treatment for NSCLC: focus on immunotherapy
@en
New modalities of cancer treatment for NSCLC: focus on immunotherapy
@nl
prefLabel
New modalities of cancer treatment for NSCLC: focus on immunotherapy
@ast
New modalities of cancer treatment for NSCLC: focus on immunotherapy
@en
New modalities of cancer treatment for NSCLC: focus on immunotherapy
@nl
P2860
P356
P1476
New modalities of cancer treatment for NSCLC: focus on immunotherapy
@en
P2093
Marianne Davies
P2860
P356
10.2147/CMAR.S57550
P407
P577
2014-01-01T00:00:00Z